Aveanna Healthcare (NASDAQ:AVAH) Price Target Cut to $5.50

Aveanna Healthcare (NASDAQ:AVAHGet Rating) had its price objective dropped by equities research analysts at Credit Suisse Group to $5.50 in a report released on Friday, Stock Target Advisor reports. Credit Suisse Group’s price target indicates a potential upside of 172.28% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Jefferies Financial Group lowered shares of Aveanna Healthcare from a “buy” rating to a “hold” rating and set a $2.50 target price on the stock. in a research report on Friday. Royal Bank of Canada reduced their price objective on Aveanna Healthcare from $16.00 to $9.00 and set an “outperform” rating on the stock in a report on Thursday, March 31st. Stephens downgraded Aveanna Healthcare from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $5.50 to $3.50 in a research report on Tuesday, June 21st. Truist Financial cut Aveanna Healthcare from a “buy” rating to a “hold” rating and set a $2.50 price target on the stock. in a report on Tuesday, July 5th. Finally, Raymond James dropped their price objective on Aveanna Healthcare from $12.00 to $8.00 and set a “strong-buy” rating for the company in a report on Thursday, March 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $5.73.

Aveanna Healthcare Trading Down 9.4 %

AVAH stock opened at $2.02 on Friday. The business has a fifty day moving average price of $2.66 and a 200 day moving average price of $3.91. The company has a debt-to-equity ratio of 1.84, a current ratio of 0.78 and a quick ratio of 0.78. Aveanna Healthcare has a fifty-two week low of $2.07 and a fifty-two week high of $11.04. The stock has a market capitalization of $373.15 million, a price-to-earnings ratio of -3.88 and a beta of 1.21.

Aveanna Healthcare (NASDAQ:AVAHGet Rating) last released its quarterly earnings results on Wednesday, May 11th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). The business had revenue of $450.53 million during the quarter, compared to the consensus estimate of $432.77 million. Aveanna Healthcare had a negative net margin of 5.70% and a positive return on equity of 8.90%. Analysts expect that Aveanna Healthcare will post 0.32 EPS for the current fiscal year.

Insider Transactions at Aveanna Healthcare

In other news, insider Tony Strange purchased 36,000 shares of the business’s stock in a transaction that occurred on Thursday, May 19th. The shares were acquired at an average cost of $2.90 per share, for a total transaction of $104,400.00. Following the transaction, the insider now directly owns 1,680,134 shares of the company’s stock, valued at approximately $4,872,388.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Tony Strange purchased 36,000 shares of the firm’s stock in a transaction dated Thursday, May 19th. The stock was bought at an average price of $2.90 per share, with a total value of $104,400.00. Following the acquisition, the insider now directly owns 1,680,134 shares of the company’s stock, valued at $4,872,388.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David Afshar acquired 12,036 shares of the stock in a transaction that occurred on Monday, May 16th. The stock was purchased at an average price of $2.86 per share, with a total value of $34,422.96. Following the transaction, the chief financial officer now owns 272,380 shares in the company, valued at $779,006.80. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 90,136 shares of company stock worth $259,733. 8.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aveanna Healthcare

Several institutional investors and hedge funds have recently modified their holdings of the business. LGT Capital Partners LTD. lifted its stake in Aveanna Healthcare by 10.3% in the second quarter. LGT Capital Partners LTD. now owns 1,600,000 shares of the company’s stock valued at $3,616,000 after buying an additional 150,000 shares in the last quarter. Delphia USA Inc. acquired a new stake in shares of Aveanna Healthcare during the first quarter worth $60,000. Goldman Sachs Group Inc. lifted its position in Aveanna Healthcare by 1.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 384,154 shares of the company’s stock valued at $1,310,000 after acquiring an additional 4,286 shares in the last quarter. State Street Corp boosted its stake in Aveanna Healthcare by 0.9% in the 1st quarter. State Street Corp now owns 805,958 shares of the company’s stock worth $2,748,000 after purchasing an additional 7,448 shares during the period. Finally, Atria Wealth Solutions Inc. bought a new position in Aveanna Healthcare during the 1st quarter worth about $91,000. 95.00% of the stock is currently owned by institutional investors and hedge funds.

About Aveanna Healthcare

(Get Rating)

Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides private duty nursing (PDN), adult home health and hospice, home-based pediatric therapy, and enteral nutrition services in the United States. Its patient- centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals.

Read More

Stock Target Advisor logo

Analyst Recommendations for Aveanna Healthcare (NASDAQ:AVAH)

Receive News & Ratings for Aveanna Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aveanna Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.